EDSA logo

EDESA BIOTECH INC

EDSANASDAQ
🏆 #4598 by market capEarnings Dec 10 · PostUS Equity
$3.53▼ $0.13 (−3.81%)
Market closed · at close
🔔
Track EDSA
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 3.8%
7d▼ 11.5%
14d▼ 9.9%
30d▼ 24.0%
ytd▲ 141.0%
1y▲ 43.5%
🏦Market Cap
$34M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
80
Good

Trading Snapshot

Day Range
$3.48 – $3.60
52-Week Range
$0.72 – $20.32
Volume
$3.61B
Avg Volume
$4.01B
Shares Outstanding
9.6M
Next Earnings
Nov 25, 2026

Fundamentals Snapshot

Annual Revenue
$14M
Last Q Revenue
$4M
P/E Ratio
-2.1
P/S Ratio
0.0x
EPS (TTM)
$-1.57
Dividend Yield
0.00%
Dilution (1yr)
+138.3%

Why Investors Own EDSA

  • ✓High-growth profile — revenue up +33.2% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 61% gross margin and 9% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

EDSA logo

EDESA BIOTECH INC

EDSA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$8M▲ +12.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$7M▲ +49.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
8.0M▲ +138.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$12M▲ +$10M YoY
StockOtter · stockotter.space

About EDESA BIOTECH INC

Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
80/100

Analyst Ratings

ⓘ
Consensus
Buy
9 analysts
Strong Buy2
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
CNBC·2h ago

EDESA BIOTECH INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift EDSA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

EDESA BIOTECH INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.